Related Experiment Videos
Combination vigabatrin and lamotrigine therapy for intractable epilepsy
G J Schapel1, A B Black, E L Lam
1Department of Neurology, Queen Elizabeth Hospital, Woodville, Australia.
Seizure
|March 1, 1996
Summary
Combining vigabatrin (GVG) and lamotrigine (LTG) significantly reduced monthly seizure frequency in patients with intractable epilepsy. This combination therapy offers a promising option for refractory seizures, warranting further controlled trials.
Area of Science:
- Neurology
- Pharmacology
- Clinical Medicine
Background:
- Vigabatrin (GVG) and lamotrigine (LTG) are established antiepileptic drugs (AEDs) for refractory seizures.
- Individual efficacy of GVG and LTG as add-on therapy is known.
- Limited data exists on the combined use of GVG and LTG.
Purpose of the Study:
- To evaluate the efficacy and safety of combining vigabatrin (GVG) and lamotrigine (LTG) in patients with intractable epilepsy.
- To assess the reduction in monthly seizure frequency (MSF) with the combination therapy.
- To determine the optimal therapeutic window for this combination.
Main Methods:
- Prospective audit of 42 patients with intractable epilepsy.
- Add-on therapy with a combination of GVG and LTG.
- Median treatment period of eight months.
- Monitoring of monthly seizure frequency and adverse events.
Main Results:
- A statistically significant median reduction of 62% in MSF was observed (from 29 to 11).
- 69% of patients (29/42) experienced a greater than 50% reduction in MSF.
- Additional MSF reduction from the combination was 21%.
- Adverse events occurred in 57% of patients, with a 12% drop-out rate.
Conclusions:
- The combination of GVG and LTG is a viable therapeutic option for patients with intractable epilepsy.
- The study supports the need for controlled trials to confirm the additive efficacy of this combination.
- Further research is recommended to optimize dosing and minimize adverse events.